EGFR和ErbB2双重酪氨酸激酶抑制剂拉帕替尼二甲苯磺酸酯的研究进展  

Advance in research for lapatinib,a dual inhibitor of EGFR and ErbB2 tyrosine kinase activity

作　　者：封宇飞[1] 曾春兰[2] 

机构地区：[1]卫生部北京医院药学部临床药理室,北京100730 [2]广西工业职业技术学院,南宁530001

出　　处：《中国新药杂志》2007年第23期1990-1993,共4页Chinese Journal of New Drugs

摘　　要：拉帕替尼是一种人源2型表皮生长因子受体(HER2)和表皮生长因子受体(EGFR)双重酪氨酸激酶抑制剂,与卡培他滨联用治疗女性HER2阳性的乳腺癌。我们利用MEDLINE进行关键词为拉帕替尼的文献检索,对其药理作用、药动学、临床疗效及安全性,药物相互作用等进行综述。Lapatinib is a tyrosine kinase inhibitor of human epidermal growth factor receptor type 2 （HER2 or HER2/neu） and epidermal growth factor receptor （EGFR）. It is active in combination with capecitabine in treatment of women with HER2-positive metastatic breast cancer that has progressed after trastuzumab-based therapy. A literature search was conducted by MEDLINE using the key word lapatinib. Its pharmacology, pharmacokinetics, efficacy, safety and drug interactions in the treatment of breast cancer are reviewed in this paper.

关 键 词：拉帕替尼二甲苯磺酸酯 酪氨酸激酶抑制剂 乳腺癌 

分 类 号：R979.1[医药卫生—药品]